THE EFFECT OF ORAL DOXANTRAZOLE ON ALLERGEN‐INDUCED BRONCHOSPASM
Ruben Pauwels, H. Lamont, M. VAN DER STRAETEN
Abstract
Ruben Pauwels, H. Lamont, M. VAN DER STRAETEN
Abstract
The protective effect of 200 mg doxantrazole given orally on allergen-induced bronchoconstriction has been compared with 20 mg inhaled disodium cromoglycate (DSCG) in 15 patients with bronchial asthma and immediate-type hypersensitivity. Only four out of the 15 patients showed a significant inhibition of their bronchoconstriction after the oral intake of doxantrazole. Nine patients were significantly protected by 20 mg DSCG. All patients responding to doxantrazole also responded well to DSCG.
OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The protective effect of 200 mg doxantrazole given orally on allergen-induced bronchoconstriction has been compared with 20 mg inhaled disodium cromoglycate (DSCG) in 15 patients with bronchial asthma and immediate-type hypersensitivity. Only four out of the 15 patients showed a significant inhibition of their bronchoconstriction after the oral intake of doxantrazole. Nine patients were significantly protected by 20 mg DSCG. All patients responding to doxantrazole also responded well to DSCG.
Key concepts: Medicine, University hospital, General hospital, Bronchospasm, General surgery, Library science, Family medicine, Asthma